Estimating the Incidence of First RSV Hospitalization in Children Born in Ontario, Canada.

Infant Humans Child Incidence Respiratory Syncytial Virus Infections / epidemiology Ontario / epidemiology Hospitalization Respiratory Syncytial Virus, Human
RSV administrative data hospital incidence pediatrics

Journal

Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049

Informations de publication

Date de publication:
31 Jul 2023
Historique:
received: 02 02 2023
accepted: 16 06 2023
medline: 3 8 2023
pubmed: 19 6 2023
entrez: 19 6 2023
Statut: ppublish

Résumé

Respiratory syncytial virus (RSV) contributes significantly to morbidity in children, placing substantial burdens on health systems, thus RSV vaccine development and program implementation are a public health priority. More data on burden are needed by policymakers to identify priority populations and formulate prevention strategies as vaccines are developed and licensed. Using health administrative data, we calculated incidence rates of RSV hospitalization in a population-based birth cohort of all children born over a six-year period (May 2009 to June 2015) in Ontario, Canada. Children were followed until their first RSV hospitalization, death, 5th birthday, or the end of the study period (June 2016). RSV hospitalizations were identified using a validated algorithm based on International Classification of Diseases, 10th Revision, and/or laboratory-confirmed outcomes. We calculated hospitalization rates by various characteristics of interest, including calendar month, age groups, sex, comorbidities, and gestational age. The overall RSV hospitalization rate for children <5 years was 4.2 per 1000 person-years (PY) with a wide range across age groups (from 29.6 to 0.52 per 1000 PY in children aged 1 month and 36-59 months, respectively). Rates were higher in children born at a younger gestational age (23.2 per 1000 PY for those born at <28 weeks versus 3.9 per 1000 PY born at ≥37 weeks); this increased risk persisted as age increased. While the majority of children in our study had no comorbidities, rates were higher in children with comorbidities. For all age groups, rates were highest between December and March. Our results confirm the high burden of RSV hospitalization and highlight young infants are at additional risk, namely premature infants. These results can inform prevention efforts.

Sections du résumé

BACKGROUND BACKGROUND
Respiratory syncytial virus (RSV) contributes significantly to morbidity in children, placing substantial burdens on health systems, thus RSV vaccine development and program implementation are a public health priority. More data on burden are needed by policymakers to identify priority populations and formulate prevention strategies as vaccines are developed and licensed.
METHODS METHODS
Using health administrative data, we calculated incidence rates of RSV hospitalization in a population-based birth cohort of all children born over a six-year period (May 2009 to June 2015) in Ontario, Canada. Children were followed until their first RSV hospitalization, death, 5th birthday, or the end of the study period (June 2016). RSV hospitalizations were identified using a validated algorithm based on International Classification of Diseases, 10th Revision, and/or laboratory-confirmed outcomes. We calculated hospitalization rates by various characteristics of interest, including calendar month, age groups, sex, comorbidities, and gestational age.
RESULTS RESULTS
The overall RSV hospitalization rate for children <5 years was 4.2 per 1000 person-years (PY) with a wide range across age groups (from 29.6 to 0.52 per 1000 PY in children aged 1 month and 36-59 months, respectively). Rates were higher in children born at a younger gestational age (23.2 per 1000 PY for those born at <28 weeks versus 3.9 per 1000 PY born at ≥37 weeks); this increased risk persisted as age increased. While the majority of children in our study had no comorbidities, rates were higher in children with comorbidities. For all age groups, rates were highest between December and March.
CONCLUSIONS CONCLUSIONS
Our results confirm the high burden of RSV hospitalization and highlight young infants are at additional risk, namely premature infants. These results can inform prevention efforts.

Identifiants

DOI: 10.1093/jpids/piad045 PMID: 37335754 PMC: PMC10389057
pubmed: 37335754
pii: 7202032
doi: 10.1093/jpids/piad045
pmc: PMC10389057
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

421-430

Subventions

Organisme : SickKids-Canadian Institutes of Health Research New Investigator
ID : NI19-1065
Organisme : Public Health Ontario and by ICES

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society.

Références

Influenza Other Respir Viruses. 2016 May;10(3):205-10
pubmed: 26859306
Virus Res. 2011 Dec;162(1-2):80-99
pubmed: 21963675
N Engl J Med. 2022 Mar 3;386(9):837-846
pubmed: 35235726
Can Respir J. 2014 May-Jun;21(3):163-4
pubmed: 24914608
Euro Surveill. 2019 Jan;24(1):
pubmed: 30621817
Lancet Infect Dis. 2023 Jan;23(1):e2-e21
pubmed: 35952703
Influenza Other Respir Viruses. 2017 Mar;11(2):122-129
pubmed: 28058797
J Infect Dis. 2022 Aug 26;226(3):374-385
pubmed: 35668702
Can Commun Dis Rep. 2022 Jul 07;48(7-8):363-366
pubmed: 37426290
Epidemiol Infect. 2019 Jan;147:e246
pubmed: 31364578
N Engl J Med. 2009 Feb 5;360(6):588-98
pubmed: 19196675
Pediatrics. 2013 Aug;132(2):e341-8
pubmed: 23878043
Pediatr Infect Dis J. 2007 Mar;26(3):210-6
pubmed: 17484216
Euro Surveill. 2018 Jan;23(3):
pubmed: 29386093
JAMA Pediatr. 2015 Sep;169(9):846-54
pubmed: 26192102
Clin Infect Dis. 2017 Sep 15;65(6):1020-1025
pubmed: 28903503
J Infect Dis. 2017 Jan 1;215(1):17-23
pubmed: 27738052
Pediatr Infect Dis J. 2015 Feb;34(2):145-8
pubmed: 25232778
N Engl J Med. 2023 Apr 20;388(16):1451-1464
pubmed: 37018474
PLoS One. 2016 Mar 09;11(3):e0150416
pubmed: 26958849
Am J Dis Child. 1986 Jun;140(6):543-6
pubmed: 3706232
Pediatr Infect Dis J. 2019 Apr;38(4):362-369
pubmed: 30882725
N Engl J Med. 2002 Dec 26;347(26):2097-103
pubmed: 12501221
Med J Aust. 2019 Jun;210(10):444-445
pubmed: 31111497
Pediatr Infect Dis J. 2013 Oct;32(10):1073-6
pubmed: 23732222
Pediatrics. 2021 Apr;147(4):
pubmed: 33737374
Vaccine. 2019 Nov 28;37(50):7355-7362
pubmed: 28302410
Epidemiol Infect. 2016 Jun;144(8):1612-21
pubmed: 26626237
Pediatr Infect Dis J. 2016 Jan;35(1):61-5
pubmed: 26398871
Can Respir J. 2011 Mar-Apr;18(2):e10-9
pubmed: 21499597
Lancet. 2010 May 1;375(9725):1545-55
pubmed: 20399493
Pediatrics. 2015 Jan;135(1):e24-31
pubmed: 25489019
CMAJ Open. 2016 Oct 17;4(4):E615-E622
pubmed: 28018874
Vaccine. 2019 Nov 28;37(50):7394-7395
pubmed: 29395536
BMC Pediatr. 2014 Aug 08;14:199
pubmed: 25102958
Vaccine. 2013 Apr 18;31 Suppl 2:B209-15
pubmed: 23598484
Thorax. 2019 Oct;74(10):986-993
pubmed: 31383776
Influenza Other Respir Viruses. 2018 Jan;12(1):113-121
pubmed: 29243369
Vaccine. 2019 Jul 18;37(31):4392-4400
pubmed: 31221563
Pediatrics. 2004 Jun;113(6):1758-64
pubmed: 15173503
J Infect Dis. 2017 Jan 1;215(1):4-7
pubmed: 27694634

Auteurs

Sarah A Buchan (SA)

Health Protection, Public Health Ontario, Toronto, Ontario, Canada.
Populations and Public Health, ICES, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, Ontario, Canada.

Hannah Chung (H)

Populations and Public Health, ICES, Toronto, Ontario, Canada.
ORCID: 0000-0002-9463-3591

Teresa To (T)

Populations and Public Health, ICES, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.

Nick Daneman (N)

Health Protection, Public Health Ontario, Toronto, Ontario, Canada.
Populations and Public Health, ICES, Toronto, Ontario, Canada.
Sunnybrook Research Institute, Toronto, Ontario, Canada.
Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.

Astrid Guttmann (A)

Populations and Public Health, ICES, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada.

Jeffrey C Kwong (JC)

Health Protection, Public Health Ontario, Toronto, Ontario, Canada.
Populations and Public Health, ICES, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, Ontario, Canada.
Department of Family & Community Medicine, University of Toronto, Toronto, Ontario, Canada.
University Health Network, Toronto, Ontario, Canada.

Michelle Murti (M)

Health Protection, Public Health Ontario, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Garima Aryal (G)

Health Protection, Public Health Ontario, Toronto, Ontario, Canada.

Aaron Campigotto (A)

Health Protection, Public Health Ontario, Toronto, Ontario, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Pranesh Chakraborty (P)

Newborn Screening Ontario, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.

Jonathan Gubbay (J)

Health Protection, Public Health Ontario, Toronto, Ontario, Canada.
Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Timothy Karnauchow (T)

Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Department of Pathology and Laboratory Medicine, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.

Kevin Katz (K)

Department of Infection Prevention and Control, North York General Hospital, Toronto, Ontario, Canada.

Allison J McGeer (AJ)

Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Department of Microbiology, Sinai Health System, Toronto, Ontario, Canada.

J Dayre McNally (J)

Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
Research Institute, Children's Hospital of Eastern Ontario, Ottawa, Ontario, CanadaChildren's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.

Samira Mubareka (S)

Sunnybrook Research Institute, Toronto, Ontario, Canada.
Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

David Richardson (D)

Department of Infection Prevention and Control, William Osler Health System, Brampton, Ontario, Canada.

Susan E Richardson (SE)

Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Marek Smieja (M)

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.

George Zahariadis (G)

Newfoundland & Labrador Public Health Laboratory, St. John's, Newfoundland and Labrador, Canada.

Shelley L Deeks (SL)

Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, Ontario, Canada.
Nova Scotia Department of Health and Wellness, Halifax, Nova Scotia, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Nourrisson › Estimating the Incidence of First RSV...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Estimating the Incidence of First RSV...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Estimating the Incidence of First RSV...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › Estimating the Incidence of First RSV...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Infections à Mononegavirales › Infections à Paramyxoviridae › Infections à pneumovirus › Infections à virus respiratoire syncytial › Estimating the Incidence of First RSV...
questionsmedicales.fr › Régions géographiques › Amériques › Amérique du Nord › Canada › Ontario › Estimating the Incidence of First RSV...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Services de santé › Soins aux patients › Hospitalisation › Estimating the Incidence of First RSV...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Mononegavirales › Paramyxoviridae › Pneumovirinae › Pneumovirus › Virus respiratoires syncytiaux › Virus respiratoire syncytial humain › Estimating the Incidence of First RSV...